Objective: To evaluate the effectiveness of certain noninvasive liverdamage markers in predicting liver diseases and the clinical severity of liver cirrhosis.
Liver cirrhosis is the final pathological result of various chronic liver diseases and is an important public health problem in highly developed countries; for instance, it is the fourth most common cause of death in central Europe. 1, 2 The most common causes of liver cirrhosis are alcoholic liver disease and hepatitis C infection. 3, 4 The effects of irreversible liver damage are degeneration and necrosis of hepatocytes, replacement of liver parenchyma by fibrotic tissues and regenerative nodules. 5 The diagnosis of liver diseases, including cirrhosis (alcoholic and nonalcoholic origin) and toxic hepatitis (TH; mostly caused by alcohol abuse) is based on the physical examination results, biochemical test results, symptoms, liver-imaging test results, and history of alcohol intake. 4, 6 To confirm viralrelated cirrhosis, hepatitis B surface (HBs) antigen, and hepatitis C virus (HCV) antibodies are usually determined. 7 Liver-function tests detect inflammation of and damage to the liver. These tests include aminotransferases, gamma-glutamyl transferase (GGT), albumin, bilirubin, and prothrombin time (PT). Liver diseases (mainly, cirrhosis) are characterized by the reduced synthesis of the procoagulant factors. The deficiency of these factors directly affects PT/international normalized ratio (INR) value. The changes in the coagulation systems are a hallmark of advanced liver disease. It has been documented that the value of INR in liver diseases is elevated. 8, 9 The platelets (PLTs) have a dual role in hemostasis: during primary hemostasis in PLT plug formation and during secondary hemostasis in stabilization of the PLT plug. 10 The common complication in patients with chronic liver disease is thrombocytopenia (PLT count, <150 Â 10 is caused by splenic and hepatic sequestration of PLTs, suppression of PLT production in the bone marrow (eg, caused by viruses or alcoholic etiology of liver disease), and decreased activity of the hematopoietic growth factor thrombopoietin (TPO). 10 Alanine aminotransferase (ALT) is found abundantly in the cytosol of hepatocytes, and the liver has approximately 3000 times more ALT than serum. During liver injury, ALT released from damaged cells can rapidly increase ALT activity in the serum. 11 Aspartate transaminase (AST) is present not only in the liver but also in skeletal muscles and erythrocytes. Therefore, AST activity increases in the case of hepatic injury but is less specific for hepatic injury than ALT.
11,12
The aim of this study was 2-fold. First, we evaluated the effect of liver diseases of different etiologies. Next, we evaluated that effect and the clinical severity of cirrhosis on the values of selected noninvasive indirect markers of liver damage: Bonacini score (BS), King score, and Gö teborg University Cirrhosis Index (GUCI) involving combinations of aminotransferases, INR, and PLTs.
Materials and Methods

Subjects
The 
Blood Specimen Gathering
We obtained blood specimens from fasting individuals by venipuncture after admittance and before treatment. The sera were separated by centrifugation and stored at À86 C until assayed. Besides serum, we collected a part of each blood specimen into tubes containing 3.8% liquid sodium citrate for hemostasis analyses and ethylenediaminetetraacetic acid (EDTA) for hematological analyses.
We measured ALT and AST on the ARCHITECT ci8200 Calculations GUCI, Bonacini, and King scores were calculated based on the following formulas:
Upper limit of normal AST equals 50 U/L) 13 Bonacini score
The Bonacini score has a range of possible values, from 0 to 11 ( Table 1) .
14 Possible total score derived from three laboratory parameters: platelets, ALT/AST ratio, and PT. Different points are given and added together according to the values of these parameters.
Statistical Analysis
The differences between tested and control groups were evaluated by Mann-Whitney U test. To test the hypothesis about the differences between liver diseases, we performed the analysis of variance (ANOVA) rank Kruskal-Wallis test. We considered P values less than .05 as statistically significant. The diagnostic performance of each test was calculated as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy (ACC). Accuracy is defined as the proportion of people with and without the disease who will have true results (positive and negative). We used the area under the receiver operating characteristic (ROC) curve to calculate the diagnostic performance of scores. ROC curve is the plot of sensitivity versus 1-specificity, and the area under the curve (AUC) is an effective measure of accuracy that evaluates the diagnostic ability of tests to determine the through state of subjects.
Results
The Bonacini and King scores were higher in the AC group compared with the TH group (P <.001 and P ¼ .03, respectively). The value of the Bonacini score was also higher in the NAC group than in the TH group (P <.001) (Figure 1 ). (Figure 2 ).
The diagnostic usefulness of noninvasive markers is presented in Table 2 . GUCI and King scores have the highest ability to detect (100% sensitivity) and exclude (100% specificity) nonalcoholic cirrhosis. Also, both of these indices have 100% ability to exclude toxic hepatitis. Besides nonalcoholic cirrhosis and toxic hepatitis, the GUCI index has 100% specificity in alcoholic cirrhosis. The Bonacini score has 100% specificity only for alcoholic cirrhosis. 
Discussion
Liver biopsy is still considered to be the criterion standard for the diagnosis and staging of liver diseases. 6, 16 However, liver biopsy is an invasive method, and its sensitivity in diagnosing of cirrhosis is not absolute; sampling error is common. This method is associated with difficulty in obtaining a liver specimen of adequate size (no less than 25 mm Â 1.4 mm) to represent the whole liver. 16, 17 Also, liver biopsy is associated with certain complications (eg, bleeding, pain, bile peritonitis, kidney puncture, and death). 17 If liver biopsy is associated with the potential for sampling bias, and the laboratory and clinical tests did not leave room for doubt, liver biopsy in our patients was not recommended. Figure 1 The values of King, Gö teborg University Cirrhosis Index (GUCI), and Bonacini scores in liver diseases. C indicates controls; AC, alcoholic cirrhosis; NAC, nonalcoholic cirrhosis; TH, toxic hepatitis. 
Figure 2
The values of King, Gö teborg University Cirrhosis Index (GUCI), and Bonacini scores according to the Child-Pugh score. A indicates class A; B, class B; C, class C.
In this study, we tried to examine the diagnostic value of the following simple and noninvasive fibrosis and liver disease indices, namely, INR, PLT, ALT, and AST, in special algorithm models in patients with liver alcoholic and nonalcoholic cirrhosis, as well as toxic hepatitis. The reason for this is that liver damage leads to impairment of liver functions (eg, to synthesis of proteins, such as clotting factors, which results in prolongation of prothrombin time (elevated PT and international normalized ratio [INR]).
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Another common complication in patients with chronic liver disease is thrombocytopenia (PLT count, <150 Â 10 9 /L). 10 In addition, elevated serum aminotransferases activity gives evidence of inflammation and the death of hepatocytes. 1 The combinations of aminotransferases, INR, and PLT count are proposed as serum noninvasive markers of hepatic fibrosis and indices of liver diseases. 13, 15, 18 Some of these markers may reflect alterations in hepatic function and therefore can be named as indirect markers. Most of the data about indirect markers applies only to patients with chronic hepatitis C. Our study also included patients with toxic hepatitis and cirrhosis.
The Bonacini score, based on PLT, AST, ALT, and INR values, is inexpensive, easy, and rapid to calculate. It was invented by Bonacini and coworkers, who studied 3-parameter cirrhosis discriminant score (CDS) in 79 patients with chronic hepatitis C. 15 They demonstrated that the value of the Bonacini score (possible total score from 0 to 11) is significantly higher in patients with advanced fibrosis or cirrhosis (F3-F4) than in patients with a histological fibrosis score of F0-F2. 15 At the cutoff value of 8 or greater, the CDS had a sensitivity of 46% and specificity of 98% for the diagnosis of histological fibrosis scores of 3 to 4. 15 In a study published by Colli et al, 67% of 176 total patients with chronic HCV infections were correctly classified as having high or very high risk of cirrhosis, and only 33% of cirrhotic patients required biopsy to confirm the diagnosis. 16 The
Bonacini score is an indicator that can be useful for prediction of cirrhosis (independent of etiology). We have shown that the Bonacini score has excellent efficiency for the diagnosis of alcoholic and nonalcoholic cirrhosis (AUC ¼ 0.902 and AUC ¼ 0.935, respectively). Our study also demonstrated an association between Bonacini score and stage of liver injury. The Bonacini score was approximately 50% higher in class C compared with class A. We observed the lowest values in toxic hepatitis.
The King score can predict alcoholic and nonalcoholic cirrhosis, as well as toxic hepatitis, with 98.2%, 100%, and 95.2% sensitivity, respectively. In the case of cirrhosis (of both etiologies), PPV was equal to 100%. This PPV resulted from the lack of false-negative results. Our data are consistent with those in a study by Cross and coworkers. 18 In that study, the diagnostic performance of the King score for the diagnosis of cirrhosis (AUC ¼ 0.91) was good. Also, in the same study, 17 using a cut-off value of 16.7, the King score predicted cirrhosis with 86% sensitivity, 80% specificity, and 96% NPV. The investigators proved that patients with a score of less than the aforementioned cut-off value have a low risk of cirrhosis. The results published by Bota et al 6 were similar. The authors obtained values of 90% sensitivity, 74.1% specificity, 97.8% NPV, and 76.4% accuracy for predicting cirrhosis. They also found that the The final noninvasive marker that we examined involved combinations of AST, INR, and PLT count was the GUCI index. The cut-off points were similar for nonalcoholic and alcoholic cirrhosis and toxic hepatitis (0.316, 0.309, and 0.330, respectively). There were no significant differences in the GUCI index among liver diseases. The accuracy of the GUCI score for predicting cirrhosis and toxic hepatitis ranges from 92% to 100%. The GUCI index was also studied by Ehsan et al 19 correlation between GUCI score and stage of liver fibrosis. Our study also revealed a correlation between GUCI score and severity of liver cirrhosis.
In our opinion, the imprecision of markers visible in Figures 1  and 2 did not derive from sampling errors but from the biodiversity of the study group (eg, one patient had AST activity of 30 U/L, whereas another has AST activity of 600 U/L). Despite those findings, our results indicate the high usefulness of these simple, noninvasive algorithms. However, ensuring the adequate precision of the all the individual tests is necessary for the final diagnostic evaluation of noninvasive markers.
Conclusion
Our results suggest that the results of simple blood tests with special scores can be helpful in identifying cirrhosis and toxic hepatitis, with greater accuracy in identifying cirrhosis than toxic hepatitis. Also, all the scoring indices precisely reflect the severity of liver cirrhosis; however, caution must be taken in the final diagnostic evaluation of each marker. LM
